Australia’s PBS Lists Four Adalimumab Biosimilars
‘A-Flag’ Allows Substitution For Humira As Well As Between Biosimilars
Executive Summary
Four different biosimilar versions of Humira will be listed on Australia’s PBS from the start of April, with the country’s “a-flagging” mechanism allowing substitution for the brand and between adalimumab biosimilars.